Wedbush Reiterates Outperform Rating for Mersana Therapeutics (NASDAQ:MRSN)
Wedbush reissued their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a report published on Thursday,RTT News reports. The firm currently has a $3.00 target price on the stock. Separately, William Blair started coverage on Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating on the […]
Wedbush reissued their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a report published on Thursday,RTT News reports. The firm currently has a $3.00 target price on the stock. Separately, William Blair started coverage on Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating on the […]
